Table 1.
Characteristics of the 1610 participants in the study among the 12 sentinel ART sites in Zimbabwe between 2008 and 2010
| Characteristic | N (%) |
|---|---|
| Gender | |
| Female | 1106 (68.7) |
| Male | 487 (30.3) |
| Missing data | 17 (1.1) |
| Age | |
| Median age (IQR) | 36 (30;44) |
| WHO clinical staging | |
| Stage 1 | 106 (6.6) |
| Stage 2 | 289 (18.0) |
| Stage 3 | 951 (59.1) |
| Stage 4 | 78 (4.8) |
| Missing data | 186 (11.5) |
| Previous Antiretroviral drugs (ARVs) exposure | |
| PMTCT | 63 (3.9) |
| ARVs prior to initiation | 18 (1.1) |
| Others | 6 (0.4) |
| No exposure | 1139 (70.7) |
| Missing exposure status | 384 (23.9) |
| CD4 count | |
| Median baseline CD4 count (IQR) | 168 (94;253) |
| Females | 180 (106;265) |
| Males | 136 (71;222) |
| Viral loads (copies/ml) | |
| ≥1000 | 1417 (95.67) |
| Females | 982 (66.31) |
| Males | 435 (29.36) |
| <1000 | 46 (4.33) |
| Drug resistance mutations | |
| No. with genotyping results | 1483 |
| No resistance | 1389 |
| NNRTI resistance only | 73 (4.9) |
| NRTI resistance only | 18 (1.2) |
| NRTI + NNRTI resistance | 5 (0.3) |
| PI resistance | 10 (0.7) |
| Any resistance mutation | 94 (6.3) |